Compare Davita Inc (DVA) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Msci Inc — how do they compare? Davita Inc trades at $230.26 (market cap $14.92B), while Msci Inc trades at $611.43 (market cap $44.51B). The key difference: Msci Inc is far larger — about 3× Davita Inc's market cap, and Msci Inc pays a 1.34% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | MSCI | |
|---|---|---|
Market Cap | $14.92B | $44.51B |
Sector | Health | Financials |
52-Week High | $235.71 | $643.83 |
52-Week Low | $103.87 | $511.84 |
Enterprise Value | $27.47B | $50.68B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
MSCI trades at $620.23, up 2.57% with bullish technical signals and strong earnings beats. The company shows robust fundamentals with 2025 revenue of $3.13B and net income of $1.20B, supported by high margins. Recent news highlights strategic partnerships with UBS and acquisitions to enhance private markets and climate risk capabilities, reinforcing growth prospects amid positive analyst sentiment.
Outlook remains positive with a consensus price target of $718.14, though elevated P/E of 35.42 and high debt levels pose valuation and financial risks. Earnings growth and strategic expansions are key catalysts, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
